MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to ROS augmenting agents
Ontology highlight
ABSTRACT: Through a small scale metabolic-modulator screening, we have identified dimethyl fumarate (DMF), a FDA approved drug for multiple sclerosis, which suppresses neuroblastoma cell growth in vitro and in vivo. Mechanistically, DMF suppresses neuroblastoma cell growth through inducing ROS and subsequently suppressing MYCN expression.
ORGANISM(S): Homo sapiens
PROVIDER: GSE98241 | GEO | 2018/04/18
REPOSITORIES: GEO
ACCESS DATA